Report

SIGA Technologies - Additional international deal possible in Q2

SIGA recently reported Q121 results, which featured $3.4m of revenue for the delivery of oral TPOXX to the Public Health Agency of Canada (PHAC). The company also announced that in April it delivered an additional $6.9m worth of product to the agency. Importantly, during the Q121 earnings call, SIGA announced it is working towards sales to one or more new jurisdictions in 2021, with the next sale estimated to occur by the end of June of this year. Precise details on this upcoming contract are unknown.
Underlying
Siga Technologies Inc.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Sean Conroy

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch